Impact of prior treatment in the efficacy and tolerability of tirbanibulin ointment 1% for actinic keratosis: pooled results from two Phase 3 studies

Main Article Content

Todd Schlesinger
Clinical Research Center of The Carolinas

Neal Bhatia
Therapeutics Clinical Research, San Diego, CA, USA

Brian Berman
University of Miami Miller School of Medicine

Ayman Grada
Almirall

Laura Padulles
Almirall, Barcelona, Spain

Francisco Hernandez
Almirall, Spain

David Cutler
Athenex

Mark Lebwohl
Mount Sinai

Keywords

actinic keratosis

Abstract

N/A

References

1. Blauvelt A et al. New Engl J Med 2021;384:512-20.

Article Sidebar

Poster PDF
Published
Mar 4, 2022
DOI https://doi.org/10.25251/skin.6.supp.26

Article Details

How to Cite
Schlesinger, T., Bhatia, N., Berman, B. ., Grada, A., Padulles, L., Hernandez, F., Cutler, D., & Lebwohl, M. (2022). Impact of prior treatment in the efficacy and tolerability of tirbanibulin ointment 1% for actinic keratosis: pooled results from two Phase 3 studies. SKIN The Journal of Cutaneous Medicine, 6(2), s26. https://doi.org/10.25251/skin.6.supp.26
Issue
Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.